SrasV1, PubMed, Curation, bibRecord, 001157

Anti-SARS coronavirus agents: a patent review (2008 - present).

Identifieur interne : 001157 ( PubMed/Curation ); précédent : 001156; suivant : 001158

Anti-SARS coronavirus agents: a patent review (2008 - present).

Auteurs : Vathan Kumar ; Young-Sik Jung ; Po-Huang Liang

Source :

Expert opinion on therapeutic patents [ 1744-7674 ] ; 2013.

RBID : pubmed:23905913

Descripteurs français

KwdFr :
- ARN viral (), Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Brevets comme sujet, Helicase (antagonistes et inhibiteurs), Humains, Immunothérapie, Inhibiteurs de protéases (pharmacologie), Inhibiteurs de protéases (usage thérapeutique), Syndrome respiratoire aigu sévère (traitement médicamenteux), Vaccins antiviraux (usage thérapeutique), Virus du SRAS ().
MESH :
- antagonistes et inhibiteurs : Helicase.
- pharmacologie : Antiviraux, Inhibiteurs de protéases.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux, Inhibiteurs de protéases, Vaccins antiviraux.
- ARN viral, Animaux, Brevets comme sujet, Humains, Immunothérapie, Virus du SRAS.

English descriptors

KwdEn :
- Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), DNA Helicases (antagonists & inhibitors), Humans, Immunotherapy, Patents as Topic, Protease Inhibitors (pharmacology), Protease Inhibitors (therapeutic use), RNA, Viral (drug effects), SARS Virus (drug effects), Severe Acute Respiratory Syndrome (drug therapy), Viral Vaccines (therapeutic use).
MESH :
- chemical , antagonists & inhibitors : DNA Helicases.
- chemical , drug effects : RNA, Viral.
- chemical , pharmacology : Antiviral Agents, Protease Inhibitors.
- chemical , therapeutic use : Antiviral Agents, Protease Inhibitors, Viral Vaccines.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- Animals, Humans, Immunotherapy, Patents as Topic.

Abstract

A novel coronavirus (CoV), unlike previous typical human coronaviruses (HCoVs), was identified as causative agent for severe acute respiratory syndrome (SARS). SARS first surfaced as a pandemic in late 2002 and originated in southern China. SARS-CoV rapidly spread to > 30 countries by 2003, infecting nearly 8,000 people and causing around 800 fatalities. After 10 years of silence, a 2012 report alarmed researchers about the emergence of a new strain of CoV causing SARS-like disease.

DOI: 10.1517/13543776.2013.823159
PubMed: 23905913

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001157

Links to Exploration step

pubmed:23905913

Curation

No country items

Vathan Kumar

<affiliation><nlm:affiliation>Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica , Taipei 115 , Taiwan R.O.C.</nlm:affiliation>
<wicri:noCountry code="subField">Taiwan R.O.C.</wicri:noCountry>
</affiliation>

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-SARS coronavirus agents: a patent review (2008 - present).</title>
<author><name sortKey="Kumar, Vathan" sort="Kumar, Vathan" uniqKey="Kumar V" first="Vathan" last="Kumar">Vathan Kumar</name>
<affiliation><nlm:affiliation>Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica , Taipei 115 , Taiwan R.O.C.</nlm:affiliation>
<wicri:noCountry code="subField">Taiwan R.O.C.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Jung, Young Sik" sort="Jung, Young Sik" uniqKey="Jung Y" first="Young-Sik" last="Jung">Young-Sik Jung</name>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23905913</idno>
<idno type="pmid">23905913</idno>
<idno type="doi">10.1517/13543776.2013.823159</idno>
<idno type="wicri:Area/PubMed/Corpus">001157</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001157</idno>
<idno type="wicri:Area/PubMed/Curation">001157</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001157</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-SARS coronavirus agents: a patent review (2008 - present).</title>
<author><name sortKey="Kumar, Vathan" sort="Kumar, Vathan" uniqKey="Kumar V" first="Vathan" last="Kumar">Vathan Kumar</name>
<affiliation><nlm:affiliation>Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica , Taipei 115 , Taiwan R.O.C.</nlm:affiliation>
<wicri:noCountry code="subField">Taiwan R.O.C.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Jung, Young Sik" sort="Jung, Young Sik" uniqKey="Jung Y" first="Young-Sik" last="Jung">Young-Sik Jung</name>
</author>
<author><name sortKey="Liang, Po Huang" sort="Liang, Po Huang" uniqKey="Liang P" first="Po-Huang" last="Liang">Po-Huang Liang</name>
</author>
</analytic>
<series><title level="j">Expert opinion on therapeutic patents</title>
<idno type="eISSN">1744-7674</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>DNA Helicases (antagonists & inhibitors)</term>
<term>Humans</term>
<term>Immunotherapy</term>
<term>Patents as Topic</term>
<term>Protease Inhibitors (pharmacology)</term>
<term>Protease Inhibitors (therapeutic use)</term>
<term>RNA, Viral (drug effects)</term>
<term>SARS Virus (drug effects)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Viral Vaccines (therapeutic use)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral ()</term>
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Brevets comme sujet</term>
<term>Helicase (antagonistes et inhibiteurs)</term>
<term>Humains</term>
<term>Immunothérapie</term>
<term>Inhibiteurs de protéases (pharmacologie)</term>
<term>Inhibiteurs de protéases (usage thérapeutique)</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Vaccins antiviraux (usage thérapeutique)</term>
<term>Virus du SRAS ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>DNA Helicases</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Protease Inhibitors</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Helicase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Inhibiteurs de protéases</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term>
<term>Inhibiteurs de protéases</term>
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
<term>Immunotherapy</term>
<term>Patents as Topic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>ARN viral</term>
<term>Animaux</term>
<term>Brevets comme sujet</term>
<term>Humains</term>
<term>Immunothérapie</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A novel coronavirus (CoV), unlike previous typical human coronaviruses (HCoVs), was identified as causative agent for severe acute respiratory syndrome (SARS). SARS first surfaced as a pandemic in late 2002 and originated in southern China. SARS-CoV rapidly spread to > 30 countries by 2003, infecting nearly 8,000 people and causing around 800 fatalities. After 10 years of silence, a 2012 report alarmed researchers about the emergence of a new strain of CoV causing SARS-like disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23905913</PMID>
<DateCompleted><Year>2014</Year>
<Month>04</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>09</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7674</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>23</Volume>
<Issue>10</Issue>
<PubDate><Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Expert opinion on therapeutic patents</Title>
<ISOAbbreviation>Expert Opin Ther Pat</ISOAbbreviation>
</Journal>
<ArticleTitle>Anti-SARS coronavirus agents: a patent review (2008 - present).</ArticleTitle>
<Pagination><MedlinePgn>1337-48</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1517/13543776.2013.823159</ELocationID>
<Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">A novel coronavirus (CoV), unlike previous typical human coronaviruses (HCoVs), was identified as causative agent for severe acute respiratory syndrome (SARS). SARS first surfaced as a pandemic in late 2002 and originated in southern China. SARS-CoV rapidly spread to > 30 countries by 2003, infecting nearly 8,000 people and causing around 800 fatalities. After 10 years of silence, a 2012 report alarmed researchers about the emergence of a new strain of CoV causing SARS-like disease.</AbstractText>
<AbstractText Label="AREAS COVERED" NlmCategory="METHODS">To combat SARS, scientists applied for patents on various therapeutic agents, including small-molecule inhibitors targeting the essential proteases, helicase and other proteins of the virus, natural products, approved drugs, molecules binding to the virus, neutralizing antibodies, vaccines, anti-sense RNA, siRNA and ribozyme against SARS-CoV. In this article, the patents published from 2008 to the present for the new therapeutics that could potentially be used in the prophylaxis and treatment of SARS are reviewed.</AbstractText>
<AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">The therapeutic interventions or prophylaxis discussed in this review seems to offer promising solutions to tackle SARS. Rather than being complacent about the results, we should envisage how to transform them into drug candidates that may be useful in combating SARS and related viral infections in the future.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName>
<ForeName>Vathan</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Chemical Biology and Molecular Biophysics, Taiwan International Graduate Program, Academia Sinica , Taipei 115 , Taiwan R.O.C.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jung</LastName>
<ForeName>Young-Sik</ForeName>
<Initials>YS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liang</LastName>
<ForeName>Po-Huang</ForeName>
<Initials>PH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>08</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Expert Opin Ther Pat</MedlineTA>
<NlmUniqueID>9516419</NlmUniqueID>
<ISSNLinking>1354-3776</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.6.4.-</RegistryNumber>
<NameOfSubstance UI="D004265">DNA Helicases</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004265" MajorTopicYN="N">DNA Helicases</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010330" MajorTopicYN="N">Patents as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>8</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>8</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>4</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23905913</ArticleId>
<ArticleId IdType="doi">10.1517/13543776.2013.823159</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001157 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001157 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:23905913
   |texte=   Anti-SARS coronavirus agents: a patent review (2008 - present).
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:23905913" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Anti-SARS coronavirus agents: a patent review (2008 - present).

Anti-SARS coronavirus agents: a patent review (2008 - present).

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Curation

No country items

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki